Atomoxetine (Strattera) is the first FDA-approved non-stimulant medication for ADHD. It is a selective norepinephrine reuptake inhibitor (NRI) — not a stimulant and not a controlled substance — making it an important alternative when stimulants are contraindicated or not tolerated. Full therapeutic effect requires 4–6 weeks of daily use. It carries an FDA black box warning for increased suicidal ideation in children and adolescents. It is metabolized by CYP2D6, and poor metabolizers experience significantly higher drug exposures.
Atomoxetine
Uses & FDA Indications
Atomoxetine was approved by the FDA in 2002 as the first non-stimulant ADHD treatment in decades. Its development was driven by the need for an ADHD option without the controlled substance designation, abuse potential, and cardiovascular stimulation profile of amphetamine and methylphenidate-based products.
FDA-approved indication: treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and older, adolescents, and adults. It is approved as a single agent and does not require combination with stimulants. Off-label uses include treatment of anxiety disorders (some evidence, particularly for adults with comorbid ADHD and anxiety), and nocturnal enuresis (bedwetting) in children.
Key clinical situations where atomoxetine is specifically preferred over stimulants include: substance use disorder history (no abuse or diversion potential), significant tic disorders or Tourette syndrome, comorbid anxiety that worsens with stimulants, need for 24-hour symptom coverage without evening rebound, and patients or families who are uncomfortable with Schedule II controlled substances. It may also cover ADHD symptoms across the full day including morning preparation and evening homework time, without the gap during medication off-periods common with immediate-release stimulants.
How It Works
Atomoxetine selectively inhibits the presynaptic norepinephrine transporter (NET), blocking reuptake of norepinephrine into the presynaptic neuron and increasing norepinephrine availability in the synapse. This mechanism is highly selective — atomoxetine has little affinity for the serotonin transporter (SERT) or dopamine transporter (DAT), distinguishing it from SNRIs (which also inhibit SERT) and stimulants (which primarily act on DAT and NET via different mechanisms).
The rationale for norepinephrine reuptake inhibition in ADHD stems from norepinephrine's role in prefrontal cortex function — the brain region responsible for executive function, attention regulation, and impulse control. By increasing norepinephrine tone in prefrontal circuits, atomoxetine improves attention, working memory, and behavioral inhibition. Because atomoxetine does not substantially increase dopamine in the nucleus accumbens (the brain's reward center), it lacks the abuse and euphoria potential of dopamine-releasing stimulants.
CYP2D6 pharmacogenomics significantly affects atomoxetine exposure. Poor metabolizers of CYP2D6 (about 7–10% of Caucasians, 2% of Asians) have a half-life of ~21 hours vs. ~5 hours in extensive metabolizers, resulting in plasma levels 10-fold higher at standard doses. Poor metabolizers may experience more side effects at standard doses. Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) effectively convert extensive metabolizers into "phenotypic poor metabolizers," substantially increasing atomoxetine exposure.
BLACK BOX WARNING — SUICIDALITY IN PEDIATRIC PATIENTS: Atomoxetine carries an FDA black box warning for increased risk of suicidal ideation in children and adolescents. This risk appears highest in the first few months of treatment. Families and caregivers should monitor patients closely for new or worsening depression, unusual changes in behavior, agitation, irritability, or suicidal thoughts. Contact a healthcare provider immediately if these occur. Atomoxetine is not approved for patients under age 6.
Side Effects
Common
- Decreased appetite / nausea — very common, especially early in treatment; taking with food reduces nausea
- Increased heart rate and blood pressure — norepinephrine increases sympathetic tone; modest but consistent elevations
- Insomnia or somnolence — both reported; dosing time adjustment may help
- Dry mouth — noradrenergic effect
- Urinary retention or hesitancy — noradrenergic effect on bladder; more common in adults
- Sweating — sympathomimetic effect
- Mood changes / irritability — particularly in pediatric patients early in treatment
- Weight loss — related to appetite suppression; more pronounced in children
Serious
- Suicidal ideation — black box warning; monitor closely in children and adolescents, especially during first months
- Severe liver injury — rare cases of hepatotoxicity reported; discontinue if jaundice or liver function abnormalities occur
- Cardiovascular effects — significant increases in blood pressure or heart rate; contraindicated in serious cardiac conditions; sudden death reported in children with structural cardiac disease
- Psychosis / mania — reported in patients with no prior history; may unmask latent bipolar disorder
- Growth suppression — in pediatric long-term use; height and weight monitoring required
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAO Inhibitors (phenelzine, tranylcypromine, selegiline) | Risk of severe hypertensive crisis due to combined noradrenergic effects. Contraindicated. Allow 14 days after stopping MAOI before starting atomoxetine. | Contraindicated — never combine |
| CYP2D6 Inhibitors (fluoxetine, paroxetine, bupropion, quinidine) | Substantially increase atomoxetine plasma levels by blocking CYP2D6 metabolism — converting patients to "poor metabolizer" phenotype. Can increase exposure by 6–10-fold. | High — dose adjustment required when adding strong CYP2D6 inhibitors to atomoxetine |
| Sympathomimetics (albuterol, pseudoephedrine, other stimulants) | Additive cardiovascular effects — increased heart rate and blood pressure. | Moderate — monitor cardiovascular parameters; use with caution |
| Antihypertensive Drugs | Atomoxetine may antagonize antihypertensive effects via noradrenergic pressor activity. | Moderate — monitor blood pressure; antihypertensive dose adjustments may be needed |
| SSRIs / SNRIs | SSRIs that are CYP2D6 inhibitors (fluoxetine, paroxetine) significantly increase atomoxetine levels. Pharmacodynamic serotonergic interaction minimal. Combination is common for ADHD + depression or anxiety. | Moderate — SSRIs that inhibit CYP2D6 require atomoxetine dose caution; sertraline, escitalopram safer choices |
Warnings & Contraindications
Contraindications
- Concurrent use of MAO inhibitors (or within 14 days of discontinuation)
- Narrow-angle glaucoma (noradrenergic effects increase intraocular pressure)
- Pheochromocytoma or history of pheochromocytoma
- Serious cardiac disease or significant ECG abnormalities
- Hypersensitivity to atomoxetine
Black Box Warning: Suicidality
The FDA black box warning states that atomoxetine increases the risk of suicidal ideation in short-term studies in children and adolescents with ADHD. In pooled clinical trial data, suicidal thinking occurred in 0.4% of atomoxetine patients vs. 0% in placebo-treated patients. The risk is highest in the first few months of treatment and after dose changes. All patients, particularly children and adolescents, should be monitored for emergence of suicidal ideation, behavioral changes, or mood disturbance. Families and caregivers should be fully informed of this risk prior to initiating treatment.
Cardiovascular Monitoring
Atomoxetine causes small but consistent increases in heart rate (average 6 bpm) and blood pressure (average 2–3 mmHg). A cardiac history and baseline cardiovascular assessment should be obtained before prescribing. Patients with pre-existing hypertension, tachyarrhythmias, or structural cardiac disease require particular caution. Sudden death has been reported rarely in children with underlying structural cardiac abnormalities. An ECG should be considered in patients with a personal or family history of cardiac disease before initiating treatment.
Hepatotoxicity
Rare but serious cases of hepatic injury have been reported with atomoxetine. Patients should be instructed to report symptoms of liver dysfunction — jaundice, dark urine, upper right abdominal pain, unexplained nausea. Atomoxetine should be discontinued and not restarted in patients who develop jaundice or laboratory evidence of hepatic injury.
Use in Patients with Substance Use Disorders
A primary advantage of atomoxetine is its complete lack of abuse potential or controlled substance classification, making it the preferred non-stimulant ADHD pharmacotherapy in patients with substance use disorders, those in recovery, or those at risk of stimulant diversion. There is no euphoria, no intoxication, no withdrawal syndrome, and no risk of misuse with atomoxetine.
Check interactions between atomoxetine and CYP2D6 inhibitors or sympathomimetics.
Check Drug Interactions →Frequently Asked Questions
Is atomoxetine a stimulant?
No — atomoxetine is not a stimulant. It is a selective norepinephrine reuptake inhibitor (NRI) and is structurally and mechanistically unrelated to amphetamine-class stimulants (Adderall, Vyvanse) or methylphenidate (Ritalin, Concerta). Because it is not a stimulant, atomoxetine is not a controlled substance, has no abuse potential, and does not cause the same cardiovascular stimulation, insomnia pattern, or appetite suppression seen with stimulants. However, it also does not provide the rapid symptom relief that stimulants offer — full ADHD benefit requires 4–6 weeks of daily use.
When should atomoxetine be used instead of stimulants for ADHD?
Atomoxetine is preferred over stimulants in several clinical situations: when there is a history of substance use disorder (no abuse potential), when the patient has co-occurring anxiety that stimulants worsen, when tic disorders (Tourette syndrome) are present and stimulants exacerbate tics, when stimulant-related cardiovascular effects (tachycardia, blood pressure elevation) are problematic, when 24-hour symptom coverage is needed without rebound, and in settings where controlled substance prescribing is restricted or presents logistical challenges (no refills, no call-in prescriptions). Atomoxetine may also be considered when stimulants have been tried and not tolerated.
What is the black box warning for atomoxetine?
The FDA requires a black box warning for atomoxetine regarding increased risk of suicidal ideation in children and adolescents during initial treatment. In clinical trials, suicidal thinking occurred in approximately 0.4% of atomoxetine-treated patients compared to none in the placebo group. This risk is highest in the first few months of treatment. Patients, families, and caregivers should be counseled to monitor for worsening mood, unusual behavior, agitation, or suicidal thoughts and to contact a healthcare provider immediately if observed. Atomoxetine is not approved for use in pediatric patients under 6 years old.